Higher BMI, geographic atrophy may suggest poor response to aflibercept

Elevated body mass index and presence of geographic atrophy may be associated with a poor response to aflibercept in patients with age-related macular degeneration who were previously treated with ranibizumab or bevacizumab, according to a study.The retrospective chart review included 46 patients with AMD who were previously treated with Lucentis (ranibizumab, Genentech) or Avastin (bevacizumab, Genentech) before switching to Eylea (aflibercept, Regeneron).